MedPath

Tramadol

Generic Name
Tramadol
Brand Names
Conzip, Durela, Qdolo, Ralivia, Ryzolt, Seglentis, Tridural, Ultracet, Ultram, Zytram
Drug Type
Small Molecule
Chemical Formula
C16H25NO2
CAS Number
27203-92-5
Unique Ingredient Identifier
39J1LGJ30J

Overview

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Background

Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.

Indication

Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.

Associated Conditions

  • Acute Pain
  • Premature Ejaculation
  • Severe Pain
  • Acute, moderate, severe Pain
  • Moderate Pain

FDA Approved Products

TRAMADOL HYDROCHLORIDE
Manufacturer:DIRECT RX
Route:ORAL
Strength:200 mg in 1 1
Approved: 2023/05/23
NDC:61919-893
TRAMADOL HYDROCHLORIDE
Manufacturer:DIRECT RX
Route:ORAL
Strength:50 mg in 1 1
Approved: 2023/05/23
NDC:61919-073
TRAMADOL HCL ER
Manufacturer:DIRECT RX
Route:ORAL
Strength:100 mg in 1 1
Approved: 2023/05/23
NDC:61919-818
TRAMADOL HYDROCHLORIDE
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:300 mg in 1 1
Approved: 2024/03/06
NDC:70518-2795
Tramadol Hydrochloride
Manufacturer:Medsource Pharmaceuticals
Route:ORAL
Strength:100 mg in 1 1
Approved: 2024/02/27
NDC:45865-261

Singapore Approved Products

TRADOL INJECTION 50 mg/ml
Manufacturer:SHIN POONG PHARMACEUTICAL CO LTD
Form:INJECTION
Strength:50 mg/ml
Online:Yes
Approved: 1998/09/23
Approval:SIN10057P
ACUGESIC CAPSULE 50 mg
Manufacturer:DUOPHARMA (M) SDN BHD
Form:CAPSULE
Strength:50 mg
Online:Yes
Approved: 1996/10/02
Approval:SIN08953P
TRAMADOL STADA INJECTION 100 mg/2 ml
Manufacturer:B.Braun Melsungen AG
Form:INJECTION
Strength:100 mg/2 ml
Online:Yes
Approved: 1995/10/02
Approval:SIN08367P
TRACIDOL INJECTION 100mg/2ml
Manufacturer:Y.S.P. Industries (M) Sdn. Bhd.
Form:INJECTION, SOLUTION
Strength:100mg
Online:Yes
Approved: 2017/07/24
Approval:SIN15303P
TRAMADOL 50 STADA CAPSULE 50 mg
Manufacturer:STADA Arzneimittel AG
Form:CAPSULE
Strength:50 mg
Online:Yes
Approved: 1995/10/02
Approval:SIN08365P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath